<DOC>
	<DOCNO>NCT01892345</DOCNO>
	<brief_summary>The primary objective study assess efficacy safety eculizumab treatment compare placebo relapse NMO patient use time first relapse study design .</brief_summary>
	<brief_title>A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients ( PREVENT Study )</brief_title>
	<detailed_description />
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>Key 1 . Male female patient ≥ 18 year old 2 . Diagnosis NMO NMO spectrum disorder 3 . All patient must NMOIgG seropositive 4 . Clinical evidence least 2 relapse last 12 month 3 relapse last 24 month ( least 1 relapse 12 month prior Screening ) 5 . EDSS score ≤7 6 . Immunosuppressive therapy allow provided patient stable maintenance dose prior Screening remain stable dose duration study Key 1 . Use rituximab within 3 month prior screen 2 . Use mitoxantrone within 3 month prior screen 3 . Use IVIg within 3 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neuromyelitis Optica</keyword>
	<keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
	<keyword>Devic 's disease , Transverse Myelitis</keyword>
	<keyword>Optic Neuritis</keyword>
	<keyword>relapse</keyword>
	<keyword>eculizumab</keyword>
	<keyword>soliris</keyword>
	<keyword>NMO-IgG</keyword>
	<keyword>CNS Autoimmune Disorders</keyword>
	<keyword>Demyelinating Disorders</keyword>
</DOC>